Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-11-20
2007-11-20
Ewoldt, G. R. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S141100, C424S145100, C424S135100, C424S185100, C424S178100, C424S133100, C530S387300, C530S388250, C530S388260
Reexamination Certificate
active
10661366
ABSTRACT:
Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating patients afflicted with blood coagulation with such ligands, and a nucleic acid that encodes, or a cell that expresses such ligands, are provided.
REFERENCES:
patent: 4395396 (1983-07-01), Eibl et al.
patent: 4873316 (1989-10-01), Meade et al.
patent: 5932706 (1999-08-01), Mertens et al.
patent: 6391299 (2002-05-01), Blackburn et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: WO 95/13300 (1995-05-01), None
patent: WO 97/26010 (1997-07-01), None
patent: WO 9813067 (1998-04-01), None
patent: WO 99/01476 (1999-01-01), None
patent: WO 02/081496 (2002-10-01), None
patent: WO 02/090566 (2002-11-01), None
Janeway et al. Immunobiology, third edition, 1997, Garland Press, pp. 3:7 to 3:11.
Watson et al., Molecular Biology of the Gene, fourth edition, 1987, The Benjamin/Cummings Publishing Company, Inc., p. 840.
Ames, R.S. et al., “Conversion of Murine Fabs Isolated From a Combinatorial Phage Display Library to Full Length immunoglobulins”,J. immunol. Methods, 1995, pp. 177-186.
Bajaj, S. P. et al., A Monoclonal Antibody to Factor IX That Inhibits the Factor V111: Ca Potentiation of FactorX Activation, The Journal of Biological Chemistry, 260(21), pp. 11574-11580 (1985).
Bessos, H., et al., The Characterization of a Panel of Monoclonal Antibodies to Human Coagulation Factor IX, Thrombosis Research, 40, pp. 863-867 (1985).
Cao, Y. et al., Bispecific Antibodies as Novel Bioconjugates, Bioconjugate Chemistry, 9(6), pp. 635-644 (1998).
Cohen, F.E., et al., The Combinatorial Approach, Protein Structure Prediction-A Practical Approach (Ed. M.J.E. Stemberg), Oxford University Press, Ch. 9, pp. 207-227 (1996).
Engelhardt, 0., et al.,Two-Step Cloning of Antibody Variable Domains in a Phage Display Vector, Biotechniques, 17, p. 44-46 (1994).
Esser, C., et al., Immunoglobulin Class Switching: Molecular and Cellular Analysis, Annu. Rev. Immunol., 8, pp. 717-735 (1990).
Evan, G. I., et al., Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product, Mol. Cell. Biol., 5(12), p. 3610-3616 (1985).
Fay, P.J., et al.,Factor Villa A2 Subunit Residues 558-565 Represent a Factor IXa Interactive Site, Journal of Biological Chemistry, 269(32), p. 20522-20527 (1994).
Frazier, D., et al., Mapping of Monoclonal Antibodies to Human Factor IX, Blood, 74(3), p. 971-977 (1989).
Gao, C., et al., Making Artificial Antibodies: A Format for Phage Display of Combinatorial Heterodimeric Arrays, Proc. Natl. Acad. Sci., 96, p. 6025-6030 (1999).
Grassy, G., et al., Computer-Assisted Rational Design of Immunosuppressive Compounds, Nature Biotechnology, 16, p. 748-752 (1998).
Greer, J., et al., Application of the Three-Dimensional Structures of Protein Target Molecules in Structure-Based Drug Design, Journal of Medicinal Chemistry, 37(8), p. 1035-1054 (1994).
Harlow, E., et al., 2. Antibody Molecules, Antibodies-A Laboratory Manual; pp. 7-22 (1988).
Harlow, E., et al., 3. Antibody-Antigen Interactions, Antibodies-A Laboratory Manual; p. 23-35(1988).
Harlow, E., et al., 6. Monoclonal Antibodies, Antibodies-A Laboratory Manual; p. 139-243(1988).
Hochuli, E., et al., Genetic Approach to Facilitate Purification of Recombinant Proteins with a Novel Metal Chelate Adsorbent, Biotechnology, 6, p. 1321-1325 (1988).
Huston, J. S., et al., Medical Applications of Single-Chain Antibodies, Intern. Rev. Immunol., 10, p. 195-217 (1993).
Jones, D.T., et al., Protein Folds and Their Recognition from Sequence, Protein Structure Prediction—A Practical Approach (Ed. M.J.E. Stemberg), Oxford University Press, Ch. 8,. p. 174-206 (1996).
Jones, P.T., et al., Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse, Nature, 321, p. 522-525 (1986).
Jorquera, J. I., et al., Synthetic Peptides Derived from Residues 698-710 of Factor Vtll Inhibit Factor. IXa Activity, Circulation, 86, Abstract No. 2725, p. 1-685 (1992).
Karpen, M.E., et al., Modelling Protein Conformation by Molecular Mechanics and Dynamics, Protein Structure Prediction—A Practical Approach (Ed. M.J.E. Stemberg), Oxford University Press, Ch. 10, p. 229-261 (1996).
Kemp, D.S., Peptidomimetics and the Template Approach to Nucleation of B-sheets and a helices in Peptides, TIBTECH, 8, p. 249-255 (1990).
Kerschbaumer, R.J. et al., Single-Chain Fv Fusion Proteins Suitable as Coating and Detecting Reagents in a Double Antibody Sandwich Enzyme-Linked Immunosorbent Assay, Analytical Biochemistry, 249, p. 219-227 (1997).
Kerschbaumer, R.J., et al, pDAP2: A Vector for Construction of Alkaline Phosphatase Fusion Proteins, immunotechnology, 2, p. 145-150 (1996).
Lane, R. D., A Short-Duration Polyethylene Glycol Fusion Technique for Increasing Production of Monoclonal Antibody-Secreting Hybridomas, Journal of Immunological Methods, 81, p. 223-227 (1985).
Lenting, P.J., et al., The Sequence Gluf°f'-Lys'd'd of Human Blood Coagulation Factor Vill Comprises a Binding Site for Activated Factor IX, Journal of Biological Chemistry, 271(4), p. 1935-1940 (1996).
Liles, D. K., et al, The Factor VIII Peptide Consisting of Amino Acids 698 to 712 Enhances Factor IXa Cleavage of FactorX, Blood, 90(1), Abstract No. 2054, p. 463a (1997).
Lin, H-F., et al, A Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B, Blood, 90(10), p. 3962-3966 (1997).
Malik, P., et al., Multiple Display of Foreign Peptide Epitopes on Filamentous Bacteriophage Virions, Phage Display of Peptides and Proteins (Ed. B. K. Kay et al.), Academic Press, p. 127-139 (1996).
Mann, K.G., et al., Surface-Dependent Reactions of the Vitamin K-Dependent Enzyme Complexes, Blood, 76(1), p. 1-16 (1990).
Mikaelsson, M., et al., Standardization of VIII:C Assays: A Manufacturer's View, Scandinavian Journal of Haematoloqy (Ed. Nilsson et al.), 33, p. 79-86 (1984).
Nilsson, I.M. et al., Induction of Split Tolerance and Clinical Cure in High-Responding Hemophiliacs with Factor IX Antibodies, Proc. Natl. Acad. Sci. USA, 83, p. 9169-9173 (1986).
Panka et al. “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies.”Proc. Natl. Acad. Sci. USA, May 1988, pp. 3080-3084, vol. 85, No. 9.
Persic, L., et al., An Integrated Vector System For The Eukaryotic Expression of Antibodies or Their Fragments After Selection From Phase Display Libraries, Gene, p. 9-18 (1997).
Pluckthun, A., et al., New Protein Engineering Approaches to Multivalent and Bispecific Antibody Fragments, Immunotechnology, 3, p. 83-105 (1997).
Raag, R., et al., Single-Chain Fvs, FASEB Journal, 9(1), pp. 73-80 (1995).
Rees, A.R., et al., Antibody Combining Sites: Structure and Prediction, Protein Structure Prediction—A Practical Approach (Ed. M.J.E. Stemberg), Oxford University Press, Ch. 7, p. 141-172 (1996).
Roitt, LM., et al., Molecules which Recognize Antigen, Immunology, 2nd Edition, p. 5.1-5.11(1989).
Rudikoff et al. “Single amino acid substitution altering antigen-binding specificity.”Proc. Natl. Acad. Sci. USA, 1982, pp. 1979-1983, vol. 79, No. 6.
Sadler, J.E., et al., Hemophilia A, Hemophilia B, and von Willebrand's Disease, The Molecular Basis of Blood Diseases (Ed. G. Stamatoyannopoulos et al.), p. 575-630 (1987).
Vaughan, T.J., et al., Human Antibodies By Design, Nature Biotechnology, p. 535-539(1998).
Winter, G., et al., Making Antibodies by Phage Display Technology, Annu. Rev. Immunol., 12, p. 433-455 (1994).
Zhong, D., et al., Some Human Inhibitor Antibodies Interfere with Factor VIII Binding to Factor IX, Blood, 92(1), p. 136-142 (1998).
Kerschbaumer Randolf
Scheiflinger Friedrich
Baxter Healthcare S.A.
Baxter International Inc.
Ewoldt G. R.
Szperk Michael
Townsend and Townsend / and Crew LLP
LandOfFree
Factor IXa specific antibodies displaying factor VIIIa like... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Factor IXa specific antibodies displaying factor VIIIa like..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factor IXa specific antibodies displaying factor VIIIa like... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3849405